Literature DB >> 18612822

The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.

Sang Kil Lee1, Youn Wha Kim, Sung-Gil Chi, Yeong-Shil Joo, Hyo Jong Kim.   

Abstract

Saccharomyces boulardii (S. boulardii) has beneficial effects in the treatment of intestinal inflammation; however, little is known about the mechanisms by which these effects occur. We investigated the effects of S. boulardii on the expression of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and interleukin-8 (IL-8), using human HT-29 colonocytes and a rat model of trinitrobenzene sulfonic acid (TNBS)-induced colitis. The effect of S. boulardii on gene expression was assessed by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR), and Northern blot and Western blot assays. Pharmacological inhibitors for various signaling pathways were used to determine the signaling pathways implicated in the S. boulardii regulation of PPAR-gamma and IL-8. We found that S. boulardii up-regulated and down-regulated PPAR-gamma and IL-8 expression at the transcription level, both in vitro and in vivo (P < 0.05, respectively). Saccharomyces boulardii blocked tumor necrosis factor-alpha (TNF-alpha) regulation of PPAR-gamma and IL-8 through disruption of TNF-alpha-mediated nuclear factor kappa B (NF-kappaB) activation. Furthermore, S. boulardii suppressed colitis and expression of pro-inflammatory cytokine genes in vivo (P < 0.05, respectively). Our study demonstrated that S. boulardii reduces colonic inflammation and regulates inflammatory gene expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612822     DOI: 10.1007/s10620-008-0357-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Effect of Saccharomyces boulardii on cAMP- and Ca2+ -dependent Cl- secretion in T84 cells.

Authors:  D Czerucka; P Rampal
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

Review 2.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent.

Authors:  Dallas C Jones; Xiaohong Ding; Raymond A Daynes
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

4.  Critical roles of PPAR beta/delta in keratinocyte response to inflammation.

Authors:  N S Tan; L Michalik; N Noy; R Yasmin; C Pacot; M Heim; B Flühmann; B Desvergne; W Wahli
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

Authors:  A S Neish; A T Gewirtz; H Zeng; A N Young; M E Hobert; V Karmali; A S Rao; J L Madara
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 6.  Multiple signals converging on NF-kappaB.

Authors:  F Mercurio; A M Manning
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

7.  [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells].

Authors:  Sang Kil Lee; Hyo Jong Kim; Sung Gil Chi; Jae Young Jang; Ki Deok Nam; Nam Hoon Kim; Kwang Ro Joo; Seok Ho Dong; Byung Ho Kim; Young Woon Chang; Joung Il Lee; Rin Chang
Journal:  Korean J Gastroenterol       Date:  2005-05

8.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.

Authors:  K Plein; J Hotz
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

Review 9.  Probiotics in gastroenterology: indications and future perspectives.

Authors:  D Goossens; D Jonkers; E Stobberingh; A van den Bogaard; M Russel; R Stockbrügger
Journal:  Scand J Gastroenterol Suppl       Date:  2003

10.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

Authors:  Denise Kelly; Jamie I Campbell; Timothy P King; George Grant; Emmelie A Jansson; Alistair G P Coutts; Sven Pettersson; Shaun Conway
Journal:  Nat Immunol       Date:  2003-12-21       Impact factor: 25.606

View more
  17 in total

Review 1.  IBD and the gut microbiota--from bench to personalized medicine.

Authors:  Emanuelle Bellaguarda; Eugene B Chang
Journal:  Curr Gastroenterol Rep       Date:  2015-04

2.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

3.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 4.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ.

Authors:  Sheril Alex; Katja Lange; Tom Amolo; Jeffrey S Grinstead; Anders K Haakonsson; Ewa Szalowska; Arjen Koppen; Karin Mudde; Daniëlle Haenen; Sa'ad Al-Lahham; Han Roelofsen; René Houtman; Bart van der Burg; Susanne Mandrup; Alexandre M J J Bonvin; Eric Kalkhoven; Michael Müller; Guido J Hooiveld; Sander Kersten
Journal:  Mol Cell Biol       Date:  2013-01-22       Impact factor: 4.272

Review 6.  Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

Authors:  C Pothoulakis
Journal:  Aliment Pharmacol Ther       Date:  2008-07-23       Impact factor: 8.171

7.  Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.

Authors:  Thomas W Hoffmann; Hang-Phuong Pham; Chantal Bridonneau; Camille Aubry; Bruno Lamas; Camille Martin-Gallausiaux; Marco Moroldo; Dominique Rainteau; Nicolas Lapaque; Adrien Six; Mathias L Richard; Emilie Fargier; Marie-Emmanuelle Le Guern; Philippe Langella; Harry Sokol
Journal:  ISME J       Date:  2015-07-28       Impact factor: 10.302

8.  A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice.

Authors:  B Arribas; M E Rodríguez-Cabezas; D Camuesco; M Comalada; E Bailón; P Utrilla; A Nieto; A Concha; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2009-05-26       Impact factor: 8.739

9.  The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.

Authors:  Atakan Sezer; Ufuk Usta; Irfan Cicin
Journal:  Med Oncol       Date:  2008-12-09       Impact factor: 3.064

10.  Effectiveness of Saccharomyces boulardii in a rat model of colitis.

Authors:  Mujde Soyturk; Saba Mukaddes Saygili; Huseyin Baskin; Ozgul Sagol; Osman Yilmaz; Fatih Saygili; Hale Akpinar
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.